Seeking Alpha - PAOG soon finalize CRO engagement for cannabis drug
16 10월 2020 - 10:12PM
InvestorsHub NewsWire
October 16, 2020 -- via
Seeking Alpha -- By: Manshi Mamtora, CFA, SA News Editor
- PAO Group
(OTCPK:PAOG +10.5%) anticipates entering into an agreement
with a contract research organization or CRO within the next
two weeks.
- The CRO
engagement will be a major breakthrough in advancing
PAOG's RespRx treatment for Chronic Obstructive Pulmonary
Disease (or COPD) toward FDA approval.
- PAOG acquired
RespRx from Kali-Extracts (OTCPK:KALY -8.3%), which is a cannabis treatment under
development for COPD derived from a patented cannabis extraction
method.
-
Related: PURA in management takeover deal with PAO
Group.
Press Release
Other stocks on the move:
AITX,
OZSC, and
NGCG
Source: https://seekingalpha.com/news/3622545-paog-to-soon-finalize-cro-engagement-for-cannabis-drug
New Generation Consumer (PK) (USOTC:NGCG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
New Generation Consumer (PK) (USOTC:NGCG)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
New Generation Consumer Group Inc (PK) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More New Generation Consumer Group Inc (PK) News Articles